Cost-effectiveness of different interferon beta products for relapsing-remitting and secondary progressive multiple sclerosis: Decision analysis based on long-term clinical data and switchable treatments
Shekoufeh Nikfar, Abbas Kebriaeezadeh, Rassoul Dinarvand, Mohammad Abdollahi, Mohammad-Ali Sahraian, David Henry, Ali Akbari Sari
DARU-JOURNAL OF PHARMACEUTICAL SCIENCES | BIOMED CENTRAL LTD | Published : 2013
BACKGROUND: Multiple sclerosis (MS) is a highly debilitating immune mediated disorder and the second most common cause of neurological disability in young and middle-aged adults. Iran is amongst high MS prevalence countries (50/100,000). Economic burden of MS is a topic of important deliberation in economic evaluations study. Therefore determining of cost-effectiveness interferon beta (INF β) and their copied biopharmaceuticals (CBPs) and biosimilars products is significant issue for assessment of affordability in Lower-middle-income countries (LMICs). METHODS: A literature-based Markov model was developed to assess the cost-effectiveness of three INF βs products compared with placebo for ma..View full abstract
Authors thank Iranian Society of multiple sclerosis for their kind assistance in collecting information of patients. This paper is the outcome of a PhD thesis of the first author and was supported by Faculty of Pharmacy, Tehran University of Medical Sciences.